Trevi Therapeutics Inc (TRVI)

4.03 -0.04 (-0.98%) USD  |  NASDAQ  |  Jan 08, 16:00
4.03 0.00 (0.00%) Pre-Market: 20:00
More

Trevi Therapeutics SG&A Expense (Quarterly): 2.863M for Sept. 30, 2024

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for TRVI.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense Definition

View SG&A Expense Definition
Start Trial

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Aptevo Therapeutics Inc 2.11M
Keros Therapeutics Inc 9.82M
NovaBay Pharmaceuticals Inc 2.65M
Palatin Technologies Inc 2.021M
iBio Inc 2.801M